Literature DB >> 29789901

Cell differentiation in cardiac myxomas: confocal microscopy and gene expression analysis after laser capture microdissection.

Angela Pucci1,2, Claudia Mattioli3,4, Marco Matteucci4, Daniele Lorenzini3, Francesca Panvini5, Simone Pacini5, Chiara Ippolito6, Michele Celiento7, Andrea De Martino7, Amelio Dolfi6, Beatrice Belgio3, Uberto Bortolotti7, Fulvio Basolo8, Giovanni Bartoloni9.   

Abstract

Cardiac myxomas are rare tumors with a heterogeneous cell population including properly neoplastic (lepidic), endothelial and smooth muscle cells. The assessment of neoplastic (lepidic) cell differentiation pattern is rather difficult using conventional light microscopy immunohistochemistry and/or whole tissue extracts for mRNA analyses. In a preliminary study, we investigated 20 formalin-fixed and paraffin-embedded cardiac myxomas by means of conventional immunohistochemistry; in 10/20 cases, cell differentiation was also analyzed by real-time RT-PCR after laser capture microdissection of the neoplastic cells, whereas calretinin and endothelial antigen CD31 immunoreactivity was localized in 4/10 cases by double immunofluorescence confocal microscopy. Gene expression analyses of α-smooth muscle actin, endothelial CD31 antigen, alpha-cardiac actin, matrix metalloprotease-2 (MMP2) and tissue inhibitor of matrix metalloprotease-1 (TIMP1) was performed on cDNA obtained from either microdissected neoplastic cells or whole tumor sections. We found very little or absent CD31 and α-Smooth Muscle Actin expression in the microdissected cells as compared to the whole tumors, whereas TIMP1 and MMP2 genes were highly expressed in both ones, greater levels being found in patients with embolic phenomena. α-Cardiac Actin was not detected. Confocal microscopy disclosed two different signals corresponding to calretinin-positive myxoma cells and to endothelial CD31-positive cells, respectively. In conclusion, the neoplastic (lepidic) cells showed a distinct gene expression pattern and no consistent overlapping with endothelial and smooth muscle cells or cardiac myocytes; the expression of TIMP1 and MMP2 might be related to clinical presentation; larger series studies using also systematic transcriptome analysis might be useful to confirm the present results.

Entities:  

Keywords:  Cardiac myxoma; Confocal microscopy; Gene expression; Immunohistochemistry; Laser capture microdissection; Transcription factors

Mesh:

Substances:

Year:  2018        PMID: 29789901     DOI: 10.1007/s00380-018-1189-2

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  23 in total

Review 1.  Histopathologic and clinical characterization of cardiac myxoma: review of 53 cases from a single institution.

Authors:  A Pucci; P Gagliardotto; C Zanini; S Pansini; M di Summa; F Mollo
Journal:  Am Heart J       Date:  2000-07       Impact factor: 4.749

2.  The identity and histogenesis of cardiac myxomas. A controversy put to rest.

Authors:  J T Lie
Journal:  Arch Pathol Lab Med       Date:  1989-07       Impact factor: 5.534

Review 3.  Cardiac myxoma the great imitators: comprehensive histopathological and molecular approach.

Authors:  Igor Gošev; Frane Paić; Zeljko Durić; Milorad Gošev; Sanja Ivčević; Floriana Bulić Jakuš; Bojan Biočina
Journal:  Int J Cardiol       Date:  2012-01-11       Impact factor: 4.164

Review 4.  Incidental Epstein-Barr virus associated atypical lymphoid proliferation arising in a left atrial myxoma: a case of long survival without any postsurgical treatment and review of the literature.

Authors:  Giovanni Bartoloni; Angela Pucci; Alexandra Giorlandino; Massimiliano Berretta; Carmelo Mignosa; Fabrizio Italia; Antonino Carbone; Vincenzo Canzonieri
Journal:  Cardiovasc Pathol       Date:  2012-09-28       Impact factor: 2.185

5.  Cardiac myxoma cells exhibit embryonic endocardial stem cell features.

Authors:  A Orlandi; A Ciucci; A Ferlosio; R Genta; L G Spagnoli; G Gabbiani
Journal:  J Pathol       Date:  2006-06       Impact factor: 7.996

Review 6.  Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation.

Authors:  C A Stratakis; L S Kirschner; J A Carney
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

7.  The Fas-mediated apoptotic pathway in cardiac myxoma.

Authors:  Cheng-Chung Liu; Shih-Ming Jung; Augusto Orlandi; Ta-Sen Yeh; Yu-Shen Lin; Tzu-Fang Shiu; Hsueh-Hua Wu; Jaw-Ji Chu; Pyng-Jing Lin; Pao-Hsien Chu
Journal:  Int J Surg Pathol       Date:  2010-12       Impact factor: 1.271

8.  Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues.

Authors:  Marc P Pusztaszeri; Walter Seelentag; Fred T Bosman
Journal:  J Histochem Cytochem       Date:  2005-10-18       Impact factor: 2.479

Review 9.  Cardiac myxomas.

Authors:  K Reynen
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

10.  Cytokeratin profile and neuroendocrine cells in the glandular component of cardiac myxoma.

Authors:  Angela Pucci; Giovanni Bartoloni; Elena Tessitore; J Aidan Carney; Mauro Papotti
Journal:  Virchows Arch       Date:  2003-09-13       Impact factor: 4.064

View more
  2 in total

1.  Atrial myxomas arise from multipotent cardiac stem cells.

Authors:  Mariangela Scalise; Michele Torella; Fabiola Marino; Maria Ravo; Giorgio Giurato; Carla Vicinanza; Eleonora Cianflone; Teresa Mancuso; Iolanda Aquila; Luca Salerno; Giovanni Nassa; Valter Agosti; Antonella De Angelis; Konrad Urbanek; Liberato Berrino; Pierangelo Veltri; Donatella Paolino; Pasquale Mastroroberto; Marisa De Feo; Giuseppe Viglietto; Alessandro Weisz; Bernardo Nadal-Ginard; Georgina M Ellison-Hughes; Daniele Torella
Journal:  Eur Heart J       Date:  2020-12-01       Impact factor: 29.983

Review 2.  miRNAs in Cardiac Myxoma: New Pathologic Findings for Potential Therapeutic Opportunities.

Authors:  Antonio Nenna; Francesco Loreni; Omar Giacinto; Camilla Chello; Pierluigi Nappi; Massimo Chello; Francesco Nappi
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.